Baxter International Inc BAX
We take great care to ensure that the data presented and summarized in this overview for BAXTER INTERNATIONAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BAX
View all-
Black Rock Inc. New York, NY63MShares$2.15 Billion0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA60.8MShares$2.07 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA50.4MShares$1.72 Billion0.92% of portfolio
-
Richard Pzena Pzena Investment Management LLC33.6MShares$1.15 Billion3.45% of portfolio
-
State Street Corp Boston, MA21.8MShares$743 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD16MShares$545 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA12.4MShares$424 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA9.38MShares$320 Million0.05% of portfolio
-
Harris Associates L P Chicago, IL8.46MShares$289 Million0.32% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN7.46MShares$254 Million0.06% of portfolio
Latest Institutional Activity in BAX
Top Purchases
Top Sells
About BAX
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Insider Transactions at BAX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 06
2025
|
Jeanne K Mason EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,696
+7.29%
|
-
|
Mar 06
2025
|
Jeanne K Mason EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,375
-2.32%
|
$153,125
$35.44 P/Share
|
Mar 06
2025
|
Reaz Rasul EVP,Group Pres,Healthcare |
BUY
Grant, award, or other acquisition
|
Direct |
26,220
+17.38%
|
-
|
Mar 06
2025
|
Reaz Rasul EVP,Group Pres,Healthcare |
SELL
Payment of exercise price or tax liability
|
Direct |
9,341
-8.67%
|
$326,935
$35.44 P/Share
|
Mar 06
2025
|
David S. Rosenbloom EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
17,658
+12.6%
|
-
|
Mar 06
2025
|
David S. Rosenbloom EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,922
-4.49%
|
$172,270
$35.44 P/Share
|
Mar 06
2025
|
Alok Sonig EVP,Group President,Pharma |
BUY
Grant, award, or other acquisition
|
Direct |
29,966
+18.7%
|
-
|
Mar 06
2025
|
Alok Sonig EVP,Group President,Pharma |
SELL
Payment of exercise price or tax liability
|
Direct |
10,839
-9.75%
|
$379,365
$35.44 P/Share
|
Mar 06
2025
|
Anita A Zielinski SVP, CAO and Controller |
BUY
Grant, award, or other acquisition
|
Direct |
17,123
+50.0%
|
-
|
Mar 06
2025
|
James W Borzi EVP,Chief Supply Chain Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,989
+12.02%
|
-
|
Mar 06
2025
|
James W Borzi EVP,Chief Supply Chain Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,262
-4.91%
|
$114,170
$35.44 P/Share
|
Mar 06
2025
|
Joel T. Grade EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
29,538
+19.96%
|
-
|
Mar 06
2025
|
Joel T. Grade EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,306
-4.62%
|
$150,710
$35.44 P/Share
|
Mar 06
2025
|
Heather Knight EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,674
+16.75%
|
-
|
Mar 06
2025
|
Heather Knight EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,634
-8.78%
|
$477,190
$35.44 P/Share
|
Mar 03
2025
|
David S. Rosenbloom EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,312
-1.18%
|
$44,608
$34.86 P/Share
|
Mar 03
2025
|
Alok Sonig EVP,Group President,Pharma |
SELL
Payment of exercise price or tax liability
|
Direct |
1,936
-1.71%
|
$65,824
$34.86 P/Share
|
Mar 03
2025
|
James W Borzi EVP,Chief Supply Chain Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,339
-1.98%
|
$45,526
$34.86 P/Share
|
Mar 03
2025
|
Heather Knight EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,344
-2.11%
|
$113,696
$34.86 P/Share
|
Mar 03
2025
|
Jeanne K Mason EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,479
-0.78%
|
$50,286
$34.86 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 321K shares |
---|
Payment of exercise price or tax liability | 161K shares |
---|